Biotechnology

A federal jury exonerated hedge fund Armistice Capital of all fraud claims related to Vaxart's COVID-era stock surge, a major trial loss for investors.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

Early human trial data for a new drug, UDP-003, suggests it can safely remove toxic cholesterol, a key step toward reversing arterial plaque buildup.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Atamyo's new gene therapy shows remarkable early results, potentially halting a severe, progressive muscular dystrophy that affects children.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

METiS TechBio's stock surged over 170% on its debut, as investors bet big on its AI-powered platform to build the future of precision drug delivery.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

OrganaBio's strategic acquisition of Excellos creates a coast-to-coast manufacturing entity, aiming to de-risk and accelerate the complex cell therapy supply chain.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

ICON plc opens a state-of-the-art San Antonio research unit, aiming to accelerate drug development and improve the patient trial experience.

Benchling launches Model Hub, an integrated platform to democratize AI in biotech, aiming to slash R&D timelines by embedding models into daily workflows.

With a new strategic investor and a star executive on its board, Apreo Health is poised to advance its breakthrough BREATHE Airway Scaffold for severe emphysema.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

From malaria vaccines to maglev trains, 12 finalists are celebrated for breakthroughs tackling the world's most pressing environmental and health crises.

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.